Obituary
发表于 2025-3-28 18:21:40
Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disordersthe author’s experience as an endocrinologist and an FDA representative, educator, and reviewer responsible for approval of the first statin and insulin analog, metformin, and other metabolic products.
Estimable
发表于 2025-3-28 22:23:55
http://reply.papertrans.cn/104/10303/1030279/1030279_42.png
aptitude
发表于 2025-3-29 02:51:47
http://reply.papertrans.cn/104/10303/1030279/1030279_43.png
闪光东本
发表于 2025-3-29 06:41:12
http://reply.papertrans.cn/104/10303/1030279/1030279_44.png